Page 1508 - Williams Hematology ( PDFDrive )

1482 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1483

583. Kantarjian HM, Talpaz M, Smith TL, et al: Homoharringtonine and low-dose cytara- 614. James HA: The potential application of ribozymes for the treatment of hematological
bine in the management of late chronic-phase chronic myelogenous leukemia. J Clin disorders. J Leukoc Biol 66:361, 1999.
Oncol 18:3513, 2000. 615. Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M: Purging of chronic myeloge-
584. O’Dwyer ME, La Rosee P, Nimmanapalli R, et al: Recent advances in Philadelphia nous leukemia cells by retrovirally expressed anti-bcrabl ribozymes with specific cel-
chromosome-positive malignancies: The potential role of arsenic trioxide. Semin lular compartmentalization. Cancer Gene Ther 9:71, 2002.
Hematol 39:18, 2002. 616. Cotter FE: Antisense oligonucleotides for haematological malignancies. Haematolog-
585. Kantarjian HM, O’Brien S, Corteo J, et al: Results of decitabine (5-aza-2′-deoxycy- ica 84:19, 1999.
tidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98:522, 617. Verfaillie CM, McIvor S, Zhao RCH: Gene therapy for chronic myelogenous leukemia.
2003. Mol Med Today 5:359, 1999.
586. Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged expo- 618. Wagner H, McKeough PG, Desforges J, Madoc-Jones H: Splenic irradiation in the
sure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in treatment of patients with chronic myelogenous leukemia or myelofibrosis and mye-
hematopoietic malignancies. Blood 103:1635, 2004. loid metaplasia. Cancer 58:1204, 1986.
587. Chand M, Thakuri M, Keung YK: Imatinib mesylate associated with delayed hemato- 619. McFarland JT, Kuzma C, Millard FE, Johnstone PA: Palliative irradiation of the spleen.
poietic recovery after concomitant chemotherapy. Leukemia 18:886, 2004. Am J Clin Oncol 26:178, 2003.
588. Deininger M: Resistance and relapse with imatinib in CML: Causes and conse- 620. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Results of a pro-
quences. J Natl Compr Canc Netw 6 Suppl 2:S11, 2008. spective randomized trial of early splenectomy in chronic myeloid leukemia. Cancer
589. Wu CJ, Neuberg D, Chillemi A, et al: Quantitative monitoring of BCR/ABL transcript 54:333, 1984.
during STI-571 therapy. Leuk Lymphoma 43:2281, 2002. 621. Mesa RA, Elliott MA, Tefferi A: Splenectomy in chronic myeloid leukemia and myel-
590. Druker BJ: Imatinib as a paradigm of targeted therapies. J Clin Oncol 21:239, 2003. ofibrosis with myeloid metaplasia. Blood Rev 14:121, 2000.
591. Druker BJ: STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8:S14, 622. Kalhs P, Schwarzinger I, Anderson G, et al: A retrospective analysis of the long-term
2002. effect of splenectomy on late infections, graft-versus-host disease, relapse, and sur-
592. Merx K, Muller MC, Kreil S, et al: Early reduction of BCR-ABL mRNA transcript lev- vival after allogeneic marrow transplantation for chronic myelogenous leukemia.
els predicts cytogenetic response in chronic phase CML patients treated with imatinib Blood 86:2028, 1995.
after failure of interferon alpha. Leukemia 16:1579, 2002. 623. Meera V, Jijina F, Shrikande M, et al: Twin pregnancy in a patient of chronic myeloid
593. Tam CS, Kantarjian H, Garcia-Manero G, et al: Failure to achieve a major cytogenetic leukemia on imatinib therapy. Leuk Res 32:1620, 2008.
response by 12 months defines inadequate response in patients receiving nilotinib or 624. Skoumalova I, Vondrakova J, Rohon P, et al: Successful childbirth in a patient with
dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood chronic myelogenous leukemia treated with imatinib mesylate during early preg-
112:516, 2008. nancy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152:121, 2008.
594. Nzha A, Kantarjian HM, Jain P, et al: Disease patterns for patients (pts) with chronic 625. Ali R, Ozkalemkas F, Ozçelik T, et al: Pregnancy under treatment of imatinib and
myeloid leukemia (CML) that have BCR0ABL transcript level >10% at 3 months of successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of
therapy with tyrosine kinase inhibitors (TKIs). Blood 12: Abstract 3757, 2012. discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res
595. Kantarjian HM, Shan J, Jones D, et al: Significance of increasing levels of minimal 29:971, 2005.
residual disease in patients with Philadelphia chromosome-positive chronic myeloge- 626. Shapira T, Pereg D, Lishner M: How I treat acute and chronic leukemia in pregnancy.
nous leukemia in complete cytogenetic response. J Clin Oncol 27:3659, 2009. Blood Rev 22:247, 2008.
596. Branford S, Rudzki Z, Parkinson I, et al: Real-time quantitative PCR analysis can be 627. Pye SM, Cortes J, Ault P, Hatfield A, et al: The effects of imatinib on pregnancy out-
used as a primary screen to identify patient with CML treated with imatinib who have come. Blood 111:5505, 2008.
BCR-ABL kinase domain mutations. Blood 104:2926, 2014. 628. Ault P, Kantarjian H, O’Brien S, et al: Pregnancy among patients with chronic myeloid
597. Bonifazi F, Bandini G, Rondelli D, et al: Reduced incidence of GVHD without increase leukemia treated with imatinib. J Clin Oncol 24:1204, 2006.
in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone 629. Ramasamy K, Hayden J, Lim Z, et al: Successful pregnancies involving men with
marrow transplants in CML. Bone Marrow Transplant 32:237, 2003. chronic myeloid leukaemia on imatinib therapy. Br J Haematol 137:374, 2007.
598. Baccarani M, Russo D, Rosti G, Martinelli G: Interferon-alpha for chronic myeloid 630. Breccia M, Cannella L, Montefusco E, et al: Male patients with chronic myeloid leuke-
leukemia. Semin Hematol 40:22, 2003. mia treated with imatinib involved in healthy pregnancies: Report of five cases. Leuk
599. Roy L, Guilhot J, Krahnke T, et al: Survival advantage from imatinib compared with the Res 32:519, 2008.
combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous 631. Gambacorti-Passerini CB, Tornaghi L, Marangon E, et al: Imatinib concentrations in
leukemia: Historical comparison between two phase 3 trials. Blood 108:1478, 2006. human milk. Blood 109:1790, 2007.
600. Talpaz M: Interferon-alfa-based treatment of chronic myeloid leukemia and implica- 632. Mubarek AA, Kakil IR, Al-Homsi U, et al: Normal outcome of pregnancy in chronic
tions of signal transduction inhibition. Semin Hematol 38:22, 2001. myeloid leukemia treated with interferon-alpha in 1st trimester: Report of 3 cases and
601. Kujawski LA, Talpaz M: The role of interferon-alpha in the treatment of chronic mye- review of the literature. Am J Hematol 69:115, 2002.
loid leukemia. Cytokine Growth Factor Rev 18:459, 2007. 633. Fadilah SA, Ahmad-Zailani R, Soon-Keng C, Norlaila M: Successful treatment of
602. Alimena G, Breccia M, Luciano L, et al: Imatinib mesylate therapy in chronic myeloid chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 16:1202,
leukemia patients in stable complete cytogenic response after interferon-alpha results 2002.
in a very high complete molecular response rate. Leuk Res 32:255, 2008. 634. Williams LA Garcia Gonzalez AG, Ault P, et al: Measuring the symptom burden asso-
603. Branford S, Hughes T, Milner A, et al: Efficacy and safety of imatinib in patients with ciated with the treatment of chronic myeloid leukemia. Blood 122:641, 2013.
chronic myeloid leukemia and complete or near-complete cytogenetic response to 635. Ross DM, Branford S, Seymour JF, et al: Safety and efficacy of imatinib cessation for
interferon-alpha. Cancer 110:801, 2007. CML patients with stable undetectable minimal residual disease: Results from the
604. Kolitz JE, Kempin SF, Schluger A, et al: A phase II trial of high-dose hydroxyurea in TWISTER study. Blood 122:515, 2013.
chronic myelogenous leukemia. Semin Oncol 19:27, 1992. 636. Mahon F-X, Rea D, Guilhot J, et al: Discontinuation of imatinib in patients with
605. Abhyankar D, Shende C, Saikia T, Advani SH: Hydroxyurea induced leg ulcers. J Assoc chronic myeloid leukaemia who have maintained complete molecular remission for
Physicians India 48:926, 2000. at least 2 years: The prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncol
606. Guilhot F, Chastang C, Michallet M, et al: Interferon alfa-2b combined with cytarabine 11:1029, 2010.
versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223, 1997. 637. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients
607. Hehlmann R, Heimpel H, Hasford J, et al: Randomized comparison of busulfan with chronic myelogenous leukemia in complete molecular remission for more than
and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by 2 years. Blood 109:58, 2007.
hydroxyurea. Blood 82:398, 1993. 638. Carella AM, Lerma E: Durable responses in chronic myeloid leukemia patients main-
608. Clarkson B: Chronic myelogenous leukemia: Is aggressive treatment indicated? J Clin tained with lower doses of imatinib mesylate after achieving molecular remission.
Oncol 3:135, 1985. Ann Hematol 86:749, 2007.
609. Cortes J, Jabbour E, Daley GQ, et al: Phase 1 study of lonafarnib (SCH 66336) and 639. Ghanima W, Kahrs J, Dahl TG 3rd, Tjonnfjord GE: Sustained cytogenetic response
imatinib mesylate in patients with chronic myeloid leukemia who have failed prior after discontinuation of imatinib mesylate in a patient with chronic myeloid leu-
single-agent therapy with imatinib. Cancer 110:1295, 2007. kaemia. Eur J Haematol 72:441, 2004.
610. Cortes J, Quintás-Cardama A, Garcia-Manero G, et al: Phase 1 study of tipifarnib 640. Cortes J, O’Brien S, Kantarjian H: Discontinuation of imatinib therapy after achieving
in combination with imatinib for patients with chronic myelogenous leukemia in a molecular response. Blood 104:2204, 2004.
chronic phase after imatinib failure. Cancer 110:2000, 2007. 641. Okabe S, Tauchi T, Ishii Y, et al: Sustained complete cytogenetic remission in a patient
611. Carew JS, Nawrocki ST, Kahue CN, et al: Targeting autophagy augments the antican- with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy. Int
cer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated J Hematol 85:173, 2007.
drug resistance. Blood 110:313, 2007. 642. Merante S, Orlandi E, Bernasconi P, et al: Outcome of four patients with chronic
612. Barbarotto E, Calin GA: Potential therapeutic applications of miRNA-based technol- myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90:979,
ogy in hematological malignancies. Curr Pharm Des 14:2040, 2008. 2005.
613. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH: Therapeutic application 643. Branford S, Yeung DT, Ross DM, et al: Early molecular response and female sex
of small interfering RNA directed against bcr-abl transcripts to a patient with strongly predict stable undetectable BCR-abl1, the criteria for imatinib discontinua-
imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 7:47, 2007. tion in patients with CML. Blood 121:3818, 2013.

Kaushansky_chapter 89_p1437-1490.indd 1483 9/18/15 3:42 PM